Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): a phase 3, randomized, double-blind, placebo-controlled trial

Hites et al., Journal of Infection, doi:10.1016/j.jinf.2024.106120, DisCoVeRy, NCT04315948, Feb 2024
Late treatmentDouble-blind RCT · NCT04315948 · 226 patients · France
Tixagevimab/c.. for COVID-19
Outcome
Improvement
Relative Risk · 95% CI
Lower mortality and worse 7-point scale results
Not statistically significant · p = 0.17 (mortality) and p = 0.52 (7-point scale results)

Tixagevimab/cilgavimab for COVID-19

37th treatment shown to reduce risk in May 2022, now with p = 0.026 from 20 studies, recognized in 33 countries. Efficacy is variant dependent.
Lower risk for hospitalization and cases.

No treatment is 100% effective.
Protocols combine treatments.

RCT 173 hospitalized COVID-19 patients showing no significant difference in clinical status, time to recovery, viral clearance, or mortality with tixagevimab/cilgavimab. Mortality was lower, without statistical significance. The trial was terminated early due to concerns about reduced efficacy against circulating variants.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2.75.2, BA.4.6, BQ.1.11, BA.5, BA.2.75, XBB2,3, XBB.1.53, ХВВ.1.9.13, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.14.
OutcomeImprovementEffect · pTreatmentControl
risk of death 39.9% lower · RR 0.60 · p = 0.17 39.9% lowerRR 0.60p = 0.17 12 of 123 (9.8%) 16 of 103 (15.5%) treatment 12 of 123 (9.8%), control 16 of 103 (15.5%)NNT 17odds ratio converted to relative riskday 90
risk of 7-point scale 17.6% higher · OR 1.18 · p = 0.52 17.6% higherOR 1.18p = 0.52 123 103 treatment 123, control 103inverted to make OR<1 favor treatmentRR approximated with ORprimary outcomeday 15
recovery time 1.0% lower · relative time 0.99 · p = 0.93 1.0% lowerrelative time 0.99p = 0.93 123 103 treatment 123, control 103inverted to make RR<1 favor treatment
time to discharge 9.1% lower · relative time 0.91 · p = 0.49 9.1% lowerrelative time 0.91p = 0.49 123 103 treatment 123, control 103inverted to make RR<1 favor treatment

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates.

Hites et al., 16 Feb 2024, Double Blind Randomized Controlled Trial, placebo-controlled, France, peer-reviewed, 86 authors, trial NCT04315948 (history) (DisCoVeRy). Contact: maya.hites@hubruxelles.be.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2026 France Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Jordan Georgia Switzerland Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel Haiti North Macedonia Hong Kong Qatar Panama Serbia France favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2026 France Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Taiwan Fiji Zambia Jordan Georgia Switzerland Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia France favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Abstract: Journal Pre-proof Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): a phase 3, randomized, doubleblind, placebo-controlled trial Maya Hites Clément R. Massonnaud Simon Jamard François Goehringer François Danion Jean Reignier Nathalie de Castro Denis Garot Eva Larranaga Lapique Karine Lacombe Violaine Tolsma Emmanuel Faure Denis Malvy Thérèse Staub Johan Courjon France Cazenave-Roblot Anne Ma Dyrhol Riise Paul Leturnier Guillaume Martin-Blondel Claire Roger Karolina Akinosoglou Vincent Le Moing Lionel Piroth Pierre Sellier Xavier Lescure Marius Trøseid Philippe Clevenbergh Olav Dalgard Sébastien Gallien Marie Gousseff Paul Loubet Fanny Vardon-Bounes Clotilde Visée Leila Belkhir Élisabeth Botelho-Nevers André Cabié Anastasia Kotanidou Fanny Lanternier Elisabeth Rouveix-Nordon Susana Silva Guillaume Thiery Pascal Poignard Guislaine Carcelain Alpha Diallo, Noémie Mercier, Vida Terzic Maude Bouscambert-Duchamp, Alexandre Gaymard Mary-Anne Trabaud Grégory Destras, Laurence Josset Drifa Belhadi Nicolas Billard Jérémie Guedj Thi-Hong-Lien Han Sandrine Couffin-Cadiergues Aline Dechanet Christelle Delmas, Hélène Esperou Claire Fougerou-Leurent Soizic Le Mestre Anabelle Métois Marion Noret Isabelle Bally, Sebastián Dergan-Dylon Sarah Tubiana Ouifiya Kalif Nathalie Bergaud, Benjamin Leveau Joe Eustace Richard Greil Edit Hajdu Monika Halanova Jose-Artur Paiva Anna Piekarska Jesus Rodriguez Baño Kristian Tonby Milan Trojánek Sotirios Tsiodras Serhat Unal Charles Burdet Dominique Costagliola Yazdan Yazdanpanah Nathan Peiffer-Smadja France Mentré Florence Ader PII: S0163-4453(24)00054-9 DOI: https://doi.org/10.1016/j.jinf.2024.106120 Reference: YJINF106120 To appear in: Journal of Infection Accepted date: 8 Please cite this article as: Maya Hites, Clément R. Massonnaud, Simon Jamard, François Goehringer, François Danion, Jean Reignier, Nathalie de Castro, Denis Garot, Eva Larranaga Lapique, Karine Lacombe, Violaine Tolsma, Emmanuel Faure, Denis Malvy, Thérèse Staub, Johan Courjon, France Cazenave-Roblot, Anne Ma Dyrhol Riise, Paul Leturnier, Guillaume Martin-Blondel, Claire Roger, Karolina Akinosoglou, Vincent Le Moing, Lionel Piroth, Pierre Sellier, Xavier Lescure, Marius Trøseid, Philippe Clevenbergh, Olav Dalgard, Sébastien Gallien, Marie Gousseff, Paul Loubet, Fanny Vardon-Bounes, Clotilde Visée, Leila Belkhir, Élisabeth Botelho-Nevers, André Cabié, Anastasia Kotanidou, Fanny Lanternier, Elisabeth Rouveix-Nordon, Susana Silva, Guillaume Thiery, Pascal Poignard, Guislaine Carcelain, Alpha Diallo, Noémie Mercier, Vida Terzic, Maude Bouscambert-Duchamp, Alexandre Gaymard, Mary-Anne Trabaud, Grégory Destras, Laurence Josset, Drifa Belhadi, Nicolas Billard, Jérémie Guedj, Thi-Hong-Lien Han, Sandrine Couffin-Cadiergues, Aline Dechanet, Christelle Delmas, Hélène Esperou, Claire Fougerou-Leurent, Soizic Le Mestre, Anabelle Métois, Marion Noret, Isabelle Bally, Sebastián Dergan-Dylon, Sarah Tubiana, Ouifiya Kalif, Nathalie Bergaud, Benjamin Leveau, Joe Eustace, Richard Greil, Edit Hajdu, Monika Halanova, Jose-Artur Paiva, Anna Piekarska, Jesus Rodriguez Baño, Kristian Tonby, Milan Trojánek, Sotirios Tsiodras, Serhat Unal, Charles Burdet, Dominique Costagliola, Yazdan Yazdanpanah, Nathan Peiffer-Smadja, France Mentré and Florence Ader, Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): a phase 3, randomized, double-blind, placebo-controlled..
DOI record: { "DOI": "10.1016/j.jinf.2024.106120", "ISSN": [ "0163-4453" ], "URL": "http://dx.doi.org/10.1016/j.jinf.2024.106120", "alternative-id": [ "S0163445324000549" ], "article-number": "106120", "assertion": [ { "label": "This article is maintained by", "name": "publisher", "value": "Elsevier" }, { "label": "Article Title", "name": "articletitle", "value": "Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): a phase 3, randomized, double-blind, placebo-controlled trial" }, { "label": "Journal Title", "name": "journaltitle", "value": "Journal of Infection" }, { "label": "CrossRef DOI link to publisher maintained version", "name": "articlelink", "value": "https://doi.org/10.1016/j.jinf.2024.106120" }, { "label": "Content Type", "name": "content_type", "value": "simple-article" }, { "label": "Copyright", "name": "copyright", "value": "© 2024 Published by Elsevier Ltd on behalf of The British Infection Association." } ], "author": [ { "ORCID": "http://orcid.org/0000-0001-6961-6039", "affiliation": [], "authenticated-orcid": false, "family": "Hites", "given": "Maya", "sequence": "first" }, { "affiliation": [], "family": "Massonnaud", "given": "Clément R.", "sequence": "additional" }, { "affiliation": [], "family": "Jamard", "given": "Simon", "sequence": "additional" }, { "affiliation": [], "family": "Goehringer", "given": "François", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-3907-0658", "affiliation": [], "authenticated-orcid": false, "family": "Danion", "given": "François", "sequence": "additional" }, { "affiliation": [], "family": "Reignier", "given": "Jean", "sequence": "additional" }, { "affiliation": [], "family": "de Castro", "given": "Nathalie", "sequence": "additional" }, { "affiliation": [], "family": "Garot", "given": "Denis", "sequence": "additional" }, { "affiliation": [], "family": "Lapique", "given": "Eva Larranaga", "sequence": "additional" }, { "affiliation": [], "family": "Lacombe", "given": "Karine", "sequence": "additional" }, { "affiliation": [], "family": "Tolsma", "given": "Violaine", "sequence": "additional" }, { "affiliation": [], "family": "Faure", "given": "Emmanuel", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-1948-9355", "affiliation": [], "authenticated-orcid": false, "family": "Malvy", "given": "Denis", "sequence": "additional" }, { "affiliation": [], "family": "Staub", "given": "Thérèse", "sequence": "additional" }, { "affiliation": [], "family": "Courjon", "given": "Johan", "sequence": "additional" }, { "affiliation": [], "family": "Cazenave-Roblot", "given": "France", "sequence": "additional" }, { "affiliation": [], "family": "Riise", "given": "Anne Ma Dyrhol", "sequence": "additional" }, { "affiliation": [], "family": "Leturnier", "given": "Paul", "sequence": "additional" }, { "affiliation": [], "family": "Martin-Blondel", "given": "Guillaume", "sequence": "additional" }, { "affiliation": [], "family": "Roger", "given": "Claire", "sequence": "additional" }, { "affiliation": [], "family": "Akinosoglou", "given": "Karolina", "sequence": "additional" }, { "affiliation": [], "family": "Moing", "given": "Vincent Le", "sequence": "additional" }, { "affiliation": [], "family": "Piroth", "given": "Lionel", "sequence": "additional" }, { "affiliation": [], "family": "Sellier", "given": "Pierre", "sequence": "additional" }, { "affiliation": [], "family": "Lescure", "given": "Xavier", "sequence": "additional" }, { "affiliation": [], "family": "Trøseid", "given": "Marius", "sequence": "additional" }, { "affiliation": [], "family": "Clevenbergh", "given": "Philippe", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-4470-3181", "affiliation": [], "authenticated-orcid": false, "family": "Dalgard", "given": "Olav", "sequence": "additional" }, { "affiliation": [], "family": "Gallien", "given": "Sébastien", "sequence": "additional" }, { "affiliation": [], "family": "Gousseff", "given": "Marie", "sequence": "additional" }, { "affiliation": [], "family": "Loubet", "given": "Paul", "sequence": "additional" }, { "affiliation": [], "family": "Vardon-Bounes", "given": "Fanny", "sequence": "additional" }, { "affiliation": [], "family": "Visée", "given": "Clotilde", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-1701-7584", "affiliation": [], "authenticated-orcid": false, "family": "Belkhir", "given": "Leila", "sequence": "additional" }, { "affiliation": [], "family": "Botelho-Nevers", "given": "Élisabeth", "sequence": "additional" }, { "affiliation": [], "family": "Cabié", "given": "André", "sequence": "additional" }, { "affiliation": [], "family": "Kotanidou", "given": "Anastasia", "sequence": "additional" }, { "affiliation": [], "family": "Lanternier", "given": "Fanny", "sequence": "additional" }, { "affiliation": [], "family": "Rouveix-Nordon", "given": "Elisabeth", "sequence": "additional" }, { "affiliation": [], "family": "Silva", "given": "Susana", "sequence": "additional" }, { "affiliation": [], "family": "Thiery", "given": "Guillaume", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-0021-7192", "affiliation": [], "authenticated-orcid": false, "family": "Poignard", "given": "Pascal", "sequence": "additional" }, { "affiliation": [], "family": "Carcelain", "given": "Guislaine", "sequence": "additional" }, { "affiliation": [], "family": "Diallo", "given": "Alpha", "sequence": "additional" }, { "affiliation": [], "family": "Mercier", "given": "Noémie", "sequence": "additional" }, { "affiliation": [], "family": "Terzic", "given": "Vida", "sequence": "additional" }, { "affiliation": [], "family": "Bouscambert-Duchamp", "given": "Maude", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-8194-6126", "affiliation": [], "authenticated-orcid": false, "family": "Gaymard", "given": "Alexandre", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0001-8614-1071", "affiliation": [], "authenticated-orcid": false, "family": "Trabaud", "given": "Mary-Anne", "sequence": "additional" }, { "affiliation": [], "family": "Destras", "given": "Grégory", "sequence": "additional" }, { "affiliation": [], "family": "Josset", "given": "Laurence", "sequence": "additional" }, { "affiliation": [], "family": "Belhadi", "given": "Drifa", "sequence": "additional" }, { "affiliation": [], "family": "Billard", "given": "Nicolas", "sequence": "additional" }, { "affiliation": [], "family": "Guedj", "given": "Jérémie", "sequence": "additional" }, { "affiliation": [], "family": "Han", "given": "Thi-Hong-Lien", "sequence": "additional" }, { "affiliation": [], "family": "Couffin-Cadiergues", "given": "Sandrine", "sequence": "additional" }, { "affiliation": [], "family": "Dechanet", "given": "Aline", "sequence": "additional" }, { "affiliation": [], "family": "Delmas", "given": "Christelle", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-1654-4868", "affiliation": [], "authenticated-orcid": false, "family": "Esperou", "given": "Hélène", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-2736-6769", "affiliation": [], "authenticated-orcid": false, "family": "Fougerou-Leurent", "given": "Claire", "sequence": "additional" }, { "affiliation": [], "family": "Mestre", "given": "Soizic Le", "sequence": "additional" }, { "affiliation": [], "family": "Métois", "given": "Anabelle", "sequence": "additional" }, { "affiliation": [], "family": "Noret", "given": "Marion", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-8315-6080", "affiliation": [], "authenticated-orcid": false, "family": "Bally", "given": "Isabelle", "sequence": "additional" }, { "affiliation": [], "family": "Dergan-Dylon", "given": "Sebastián", "sequence": "additional" }, { "affiliation": [], "family": "Tubiana", "given": "Sarah", "sequence": "additional" }, { "affiliation": [], "family": "Kalif", "given": "Ouifiya", "sequence": "additional" }, { "affiliation": [], "family": "Bergaud", "given": "Nathalie", "sequence": "additional" }, { "affiliation": [], "family": "Leveau", "given": "Benjamin", "sequence": "additional" }, { "affiliation": [], "family": "Eustace", "given": "Joe", "sequence": "additional" }, { "affiliation": [], "family": "Greil", "given": "Richard", "sequence": "additional" }, { "affiliation": [], "family": "Hajdu", "given": "Edit", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-9011-2238", "affiliation": [], "authenticated-orcid": false, "family": "Halanova", "given": "Monika", "sequence": "additional" }, { "affiliation": [], "family": "Paiva", "given": "Jose-Artur", "sequence": "additional" }, { "affiliation": [], "family": "Piekarska", "given": "Anna", "sequence": "additional" }, { "affiliation": [], "family": "Baño", "given": "Jesus Rodriguez", "sequence": "additional" }, { "affiliation": [], "family": "Tonby", "given": "Kristian", "sequence": "additional" }, { "affiliation": [], "family": "Trojánek", "given": "Milan", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-0463-4321", "affiliation": [], "authenticated-orcid": false, "family": "Tsiodras", "given": "Sotirios", "sequence": "additional" }, { "affiliation": [], "family": "Unal", "given": "Serhat", "sequence": "additional" }, { "affiliation": [], "family": "Burdet", "given": "Charles", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-0765-0869", "affiliation": [], "authenticated-orcid": false, "family": "Costagliola", "given": "Dominique", "sequence": "additional" }, { "affiliation": [], "family": "Yazdanpanah", "given": "Yazdan", "sequence": "additional" }, { "affiliation": [], "family": "Peiffer-Smadja", "given": "Nathan", "sequence": "additional" }, { "affiliation": [], "family": "Mentré", "given": "France", "sequence": "additional" }, { "affiliation": [], "family": "Ader", "given": "Florence", "sequence": "additional" } ], "container-title": "Journal of Infection", "container-title-short": "Journal of Infection", "content-domain": { "crossmark-restriction": true, "domain": [ "clinicalkey.fr", "clinicalkey.jp", "clinicalkey.es", "clinicalkey.com.au", "clinicalkey.com", "journalofinfection.com", "elsevier.com", "sciencedirect.com" ] }, "created": { "date-parts": [ [ 2024, 2, 16 ] ], "date-time": "2024-02-16T13:49:08Z", "timestamp": 1708091348000 }, "deposited": { "date-parts": [ [ 2024, 2, 16 ] ], "date-time": "2024-02-16T13:49:15Z", "timestamp": 1708091355000 }, "indexed": { "date-parts": [ [ 2024, 2, 17 ] ], "date-time": "2024-02-17T00:25:26Z", "timestamp": 1708129526685 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2024, 2 ] ] }, "language": "en", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 2, 1 ] ], "date-time": "2024-02-01T00:00:00Z", "timestamp": 1706745600000 } }, { "URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/", "content-version": "vor", "delay-in-days": 8, "start": { "date-parts": [ [ 2024, 2, 9 ] ], "date-time": "2024-02-09T00:00:00Z", "timestamp": 1707436800000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S0163445324000549?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S0163445324000549?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "page": "106120", "prefix": "10.1016", "published": { "date-parts": [ [ 2024, 2 ] ] }, "published-print": { "date-parts": [ [ 2024, 2 ] ] }, "publisher": "Elsevier BV", "reference": [ { "DOI": "10.1016/j.jinf.2023.06.024", "author": "Kamboj", "doi-asserted-by": "crossref", "first-page": "282", "journal-title": "J Infection", "key": "10.1016/j.jinf.2024.106120_bib1", "volume": "87", "year": "2023" }, { "DOI": "10.1016/S2213-2600(22)00180-1", "article-title": "Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial", "author": "Montgomery", "doi-asserted-by": "crossref", "first-page": "985", "issue": "10", "journal-title": "Lancet Respir Med", "key": "10.1016/j.jinf.2024.106120_bib2", "volume": "10", "year": "2022" }, { "DOI": "10.1016/S2213-2600(22)00215-6", "article-title": "Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, doubleblind, phase 3 trial", "author": "Holland", "doi-asserted-by": "crossref", "first-page": "972", "issue": "10", "journal-title": "Lancet Respir Med", "key": "10.1016/j.jinf.2024.106120_bib3", "volume": "10", "year": "2022" }, { "DOI": "10.1038/s41579-022-00841-7", "article-title": "SARS-CoV-2 variant biology: immune escape, transmission and fitness", "author": "Carabelli", "doi-asserted-by": "crossref", "journal-title": "Nat Rev Microbiol [Internet]", "key": "10.1016/j.jinf.2024.106120_bib4", "year": "2023" }, { "DOI": "10.1016/j.isci.2023.106413", "article-title": "Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sublineages", "author": "Touret", "doi-asserted-by": "crossref", "issue": "4", "journal-title": "iScience", "key": "10.1016/j.jinf.2024.106120_bib5", "volume": "26", "year": "2023" }, { "DOI": "10.1056/NEJMc2207519", "article-title": "Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants", "author": "Takashita", "doi-asserted-by": "crossref", "first-page": "468", "issue": "5", "journal-title": "NEngl J Med", "key": "10.1016/j.jinf.2024.106120_bib6", "volume": "387", "year": "2022" }, { "DOI": "10.1038/s41392-022-00997-x", "article-title": "SARS-CoV-2 Omicron variant: recent progress and future perspectives", "author": "Fan", "doi-asserted-by": "crossref", "first-page": "141", "issue": "1", "journal-title": "Signal Transduct Target Ther", "key": "10.1016/j.jinf.2024.106120_bib7", "volume": "7", "year": "2022" }, { "key": "10.1016/j.jinf.2024.106120_bib8", "unstructured": "European Medical Agency. Summary report of the Joint EMA-FDA workshop on the efficacy of monoclonal antibodies in the context of rapidly evolving SARS-CoV-2 variants [Internet]. [cited 2023 Nov 3]. Available from: 〈https://www.ema.europa.eu/en/documents/report/summary-report-joint-ema-fdaworkshop-efficacy-monoclonal-antibodies-context-rapidly-evolving-sars_en.pdf〉" }, { "key": "10.1016/j.jinf.2024.106120_bib9", "unstructured": "European Centre for Disease Prevention and Control. SARS-CoV-2 variant mutations conferring reduced susceptibility to antiviral drugs and monoclonal antibodies: a non systematic literature review for surveillance purposes. [Internet]. LU: Publications Office; 2023 [cited 2023 Nov 3]. Available from: 〈https://data.europa.eu/doi/10.2900/192733〉" }, { "DOI": "10.1093/jac/dkac048", "article-title": "Effect of remdesivir on viral dynamics in COVID-19 hospitalized patients: a modelling analysis of the randomized, controlled, open-label DisCoVeRy trial", "author": "Lingas", "doi-asserted-by": "crossref", "first-page": "1404", "issue": "5", "journal-title": "J Antimicrob Chemother", "key": "10.1016/j.jinf.2024.106120_bib10", "volume": "77", "year": "2022" } ], "reference-count": 10, "references-count": 10, "relation": {}, "resource": { "primary": { "URL": "https://linkinghub.elsevier.com/retrieve/pii/S0163445324000549" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Infectious Diseases", "Microbiology (medical)" ], "subtitle": [], "title": "Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): a phase 3, randomized, double-blind, placebo-controlled trial", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy" }
Late treatment
is less effective